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Abstract The current investigation was conducted to
evaluate the proportional distribution of the various
histologic subtypes (including newly recognized variants)
of male breast carcinomas, to determine whether any his-
tologic subtypes occur with a frequency that is markedly
discordant with the expected frequencies from published
data on parallel female breast tumors. We also aimed to
document the distribution of malignancies metastatic to the
breast. Seven hundred fifty-nine archived cases of primary
invasive carcinoma involving the male breast were retrieved
and subcategorized into histologic subtypes according to
contemporary criteria. Six hundred forty-three (84.7%)
tumors were pure infiltrating ductal carcinoma (IDC) not
otherwise specified. The most common of the remainder
included papillary carcinoma with invasion in the form of
IDC (n=34), mixed IDC and mucinous carcinoma (n=26),
and pure mucinous carcinoma (n= 2 1 ) .I n1 9c a s e s ,
metastases from other sites involved the breast, most
commonly (58%) cutaneous melanoma. Invasive carcinoma
of the male breast appears to display a morphologic spec-
trum and distribution of histologic subtypes that is com-
parable to those of the female breast, with some expected
variation. Compared with published experience on their
female counterparts, there is a two-fold increase in the
frequency of invasive papillary carcinoma in the male
breast. Finally, the most common tumor metastatic to the
male breast in this series was cutaneous melanoma.
Keywords Male.Breast.Carcinoma.Papillary.Cancer
Introduction
Breast cancer in males is relatively uncommon, with
approximately 1,450 newly diagnosed cases annually in
the United States, and an associated mortality rate that
accounts for less than 0.2% of all cancer-related deaths in
men [1, 4, 9, 15, 17, 20, 28]. However, recent epidemio-
logic studies suggest that the incidence of male breast
Virchows Arch (2006) 449:507–512
DOI 10.1007/s00428-006-0305-3
The opinions and assertions contained herein are the private views of
the authors and are not to be considered official or as necessarily
reflecting the opinion of the United States Government or any of its
subsidiaries.
A. M. Burga: R. A. Lininger:F. A. Tavassoli
Department of Gynecologic and Breast Pathology,
Armed Forces Institute of Pathology,
Washington, DC, USA
O. Fadare:F. A. Tavassoli
Department of Pathology, Yale University School of Medicine,
New Haven, CT, USA
A. M. Burga
Department of Pathology, Englewood Hospital,
Englewood, NJ, USA
O. Fadare
Department of Pathology, Wilford Hall Medical Center,
Lackland Air Force Base,
San Antonio, TX, USA
O. Fadare
Department of Pathology,
University of Texas Health Science Center at San Antonio,
San Antonio, TX, USA
R. A. Lininger
Department of Pathology, University of North Carolina,
Chapel Hill, NC, USA
O. Fadare (*)
Department of Pathology, Wilford Hall Medical Center,
2200 Bergquist Dr., Ste 1,
Lackland AFB, TX 78236, USA
e-mail: oluwolefadare@yahoo.comcancer has been steadily increasing [7, 14]. Utilizing data
from the National Cancer Institute’s Surveillance, Epide-
miology and End Results database for the 26-year period
between 1973 and 1998, Giordano et al. [7] found that the
incidence of male breast cancer increased from 0.86 to 1.08
per 100,000 population. This increasing incidence, in
addition to the better elucidation of the role of BRCA2
mutations in male breast cancer, has renewed interest in
specifically identifying the underlying pathogenesis of male
breast cancer and clarifying the specific differences, if any,
between male and female breast cancer.
On a broad demographical level, male and female breast
cancers are fundamentally similar with the main differences
lying in older age of occurrence and lower incidence of the
former. However, significant differences have been noted
between male and female breast cancers with respect to the
expression of a variety of biologic factors, including
hormone receptors such as estrogen receptor, progesterone
receptor, c-erbB-2, estrogen-inducible proteins such as pS2,
Cathepsin D, hsp27, proteins related to basement mem-
brane and extracellular matrix degradation such as the
urokinase system of plasminogen activation and their inhib-
itors, and protooncogenes such as bcl-2 [2, 6, 7, 18, 21, 22,
24, 27]. At the morphologic level, male ductal intra-
epithelial neoplasia (ductal carcinoma in situ), in contrast
to similar lesions in females, displays a distinct histologic
profile in which the majority of tumors are of the papillary
type, with cribriform, micropapillary, and solid types being
much less common [13]. In particular, the comedo-type of
DIN (comedo DCIS) is notably rare in the male breast [13].
For invasive carcinomas, the female and male tumors are
morphologically indistinguishable [26] and many published
studies on male breast cancer frequently represent the major
histologic subtypes of nonlobular breast carcinoma, such as
ductal, medullary, mucinous, and papillary [3, 7, 8, 12, 19,
22, 25]. However, these studies generally do not have the
distribution and relative frequencies of the various histo-
logic subtypes as their main focus, and as such, patholog-
ically important distinctions such as signet ring vs colloid
carcinoma (both subsumed under mucin producing carcino-
ma), or metaplastic carcinoma vs infiltrating duct carcinoma
not otherwise specified are not emphasized. Over- or un-
derepresentation of a particular histologic subtype in male
breast cancers may provide valuable insight into the
etiopathogenetic differences between male and female breast
cancers and may provide an important nidus for further
studies.
In this study, we investigated the frequencies and dis-
tribution of the various histologic subtypes in a large data
set of invasive carcinomas seen at a large tertiary center
over a 40-year period. Our goals are to document these
frequencies and distribution and to see whether any his-
tologic subtypes are notably distinct in frequency of oc-
currence in the male breast, as compared with historical
published data on similar lesions in the female breast. The
frequencies and sites of origin of metastatic tumors to the
male breast during the study period were also investigated.
Materials and methods
After approval from our institutional research review
committee, cases of invasive carcinoma involving the male
breast diagnosed between 1957 and 1997 were retrieved
from the archived institutional files of the Armed Forces
Institute of Pathology (AFIP, Washington DC, USA). The
available records and slides on each patient were reviewed.
All cases with ambiguous gender (even if one among the
multiple entries for gender was coded as female rather
than male) were excluded (n=38). Diagnostic designations
were assigned according to contemporary WHO criteria
[23]. All special types of carcinoma inclusive of mucinous,
tubular, secretory, adenoid cystic, lobular, metaplastic, etc.
(n=116) were reviewed extensively; many of these cases
had been evaluated repeatedly as part of various previous-
ly published studies from the department and slides of
good quality were available on these cases for review.
Among the 643 cases of infiltrating duct carcinoma not
otherwise specified, only cases with good quality and ade-
quate representative slides (n=365) were graded, using the
modified Scarf–Bloom Richardson scoring system. On 78
cases, the slides were so old that we could only confirm the
presence of a ductal type carcinoma. The other 200 cases
did not have all of the patients’ slides pertaining to the
lesion available and the final interpretation was based on
the descriptions of morphology in the AFIP files. Because
cases sent to AFIP are mostly for confirmation of di-
agnosis, information about therapy beyond what was in the
surgical pathology report or the accompanying cover letter
are generally not available. Some patients had repeated
material sent to AFIP as the lesion recurred, which is how
follow-up information was collected in a small subset of
cases.
Information about age, operative procedure, nodal exci-
sion, and distant metastases were retrieved from the patients’
AFIP files. Diagnostic designations were assigned largely
based on morphologic and not immunohistochemical fea-
tures since in many cases there were no blocks or unstained
slides available for additional studies. Thirty of these cases
were the subject of a previous report [13], which focused on
in situ carcinomas and were reported in 1998. Another 113
cases, 8 of which were ductal in situ and another 9 papillary
carcinomas, were subject of another report in 1969 [19]
Cases of nonhematopoietic or lymphoreticular malignancies
metastatic to the male breast during this period were also
catalogued.
508 Virchows Arch (2006) 449:507–512Results
Seven hundred and seventy-eight cases of breast carcinoma
were reported as involving the male breast during the study
period. Seven hundred fifty-nine of these cases were
considered primary to the breast and 19 as metastatic to
it. The patients ranged in age from 9 to 94 years (mean
61 years). The age distribution available for 520 cases was
as follow: 8 were ≤30 years, 22 were ≤40 years, 205 were
41 to 60 years, 251 were 61 to 80 years, and 34 were over
80 years of age. Among the 490 for whom the racial
information was available, 401 were Caucasian, not of
Hispanic origin, 82 were Black, not of Hispanic origin, 6
were Asians or Pacific Islander, 1 was Hispanic, and the
race was unknown for 269. The carcinomas ranged from
≤1 mm (microinvasive) to 12 cm. Many of the cases with
multifocal early invasion of 1 to 7 mm were associated with
large solitary or multifocal papillary intraductal carcinomas.
The various histologic subtypes and their proportional
distribution are outlined in Table 1, whereas representative
images are illustrated in Fig. 1.P u r einfiltrating duct
carcinoma not otherwise specified was the most common
histologic subtype, representing 84.7% of all cases. Six
hundred forty-three cases were in the latter group, including
34 cases associated with Paget’s disease, 17 cases with
prominent apocrine features in <50% of tumor volume (i.e.,
insufficient to qualify as apocrine carcinomas), 4 cases with
prominent medullary features (tumor circumscription, cel-
lular syncytia, sparse lymphocytic infiltrate), 2 cases of
infiltrating duct carcinoma with signet ring cells (<5% of
tumor volume), 3 cases of infiltrating duct carcinoma with
focal clear cells (<5% of tumor volume), and 3 cases of
carcinoma with osteoclast-like giant cells. Papillary intra-
ductal carcinoma with invasion in the form of infiltrating
duct carcinoma represented 4.5% (34/759 each) of all cases.
Other well-represented histologic subtypes or combinations
included mixed mucinous and infiltrating duct carcinoma
(n=26, 3.4%), pure mucinous carcinoma (21, 2.8%), and
adenoid cystic carcinoma (n=8,1.05%). Other variants each
constituted less than 1% of all cases (Table 1). Notably,
there were three cases of lobular carcinoma. As noted
previously, these diagnoses were not based on immunohis-
tochemical confirmation by immunostain for E-cadherin,
but all three showed archetypal morphologic features of
lobular carcinoma with loosely cohesive single cell files
and rare intracytoplasmic lumens. Two of these cases had
evidence of lobular development in the surrounding breast
but the slides available for review did not show lobular
intraepithelial neoplasia (LIN). There were also three cases
of mixed lobular and ductal carcinomas, in which these
areas were spatially separate. The youngest patient, a 9-
year-old boy was the only one with pure secretory
carcinoma. Five of 759 cases were microinvasive (invasive
focus less than 1 mm in maximum size in a predominantly
intraepithelial lesion); three of these five cases were
multifocal, whereas the other two were unifocal. Of the
365 cases of infiltrating duct carcinoma not otherwise
specified that were graded, 104 were grade 1, 137 were
grade 2, and 124 were grade 3. Among the 93 with lymph
nodes available for assessment, 61 (66%) cases had axillary
metastases. Forty of the women with axillary node
metastases also had distant metastases. The most common
distant metastatic sites were lung, adrenal glands, and bone.
In addition, there were 19 examples of metastases to the
breast that were documented. Of these, 58% (11/19) were
cutaneous melanomas, and 21% (4/19), 10% (2/19), and
10% (2/19) represented carcinomas from the prostate, lung,
and larynx, respectively.
Table 1 Distribution of the various histologic subtypes in 778








Carcinoma associated with Paget’s disease 34
Carcinoma with prominent apocrine features 17
Carcinoma with medullary features 4
Carcinoma with osteoclast-like giant cells 3
Carcinoma with focal signet rings 2
Carcinoma with focal clear cells 2
Pleomorphic carcinoma 2
Carcinoma with no notable distinctive
features
579
Papillary intraductal carcinoma with
invasion in the form of infiltrating duct
carcinoma
34 4.48
Mixed infiltrating duct and mucinous
carcinoma
26 3.4
Pure mucinous carcinoma 21 2.8
Adenoid cystic carcinoma 8 1.05
Tubular carcinoma 6 0.8
Small cell carcinoma 6 0.8
Invasive lobular carcinoma 3 0.39
Solid neuroendocrine carcinoma 3 0.39
Mixed lobular and ductal carcinoma 3 0.39
Adenocarcinoma with spindle cell
metaplasia
2 0.26
Pure signet ring carcinoma (no in situ
component)
1 0.13
Invasive cribriform carcinoma 1 0.13
Secretory carcinoma 1 0.13




aSubsets included for information only (not WHO categories)
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subtypes. a and b Gross and microscopic images of infiltrating duct
carcinoma, the most frequently encountered histologic subtype
(b original magnification ×160). c A colloid (mucinous) carcinoma
(right field) occurring in a gynecomastoid breast (left field) (original
magnification ×100). d The single case of a secretory carcinoma was
in a 9-year-old boy, the youngest patient in this series (original
magnification ×140). e and f Examples of papillary intraductal
carcinoma with invasion in the form of infiltrating duct carcinoma
[original magnifications: ×100 (e), ×120 (f)]
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The frequency, distribution, and morphologic spectrum of
the various histologic subtypes of male breast cancer as
comparedwithitsfemalecounterpartmayprovideavaluable
insight into the etiology and/or pathogenesis of both. This
was perhaps best illustrated in the study of ductal carcinoma
in situ by Hittmair et al. [13]. The authors showed that in the
male breast, papillary DCIS occurred with a much higher
frequency (46% of pure lesions) than expected, while solid,
micropapillary, and cribriform patterns occurred with a
much lower frequency (22% of pure DCIS combined).
Notably, only 5 of 114 cases were of comedo-type DCIS
and only 7 of 114 cases were considered high grade. The
authors concluded that predominance of papillary patterns
among intraepithelial male breast lesions is a reflection of
the relative abundance of ducts and the poorly developed
terminal-ductal lobular units in male breast. Given the rarity
of true comedo DIN in male breast, the authors speculated
that the fully developed lobular environment and the female
type hormonal milieu may be a requirement for develop-
ment of comedo DIN [13].
In this study, we investigated in detail the frequencies and
distribution of the various histologic subtypes in a large data
set of invasive carcinomas seen at a large tertiary center over
a 40-year period. Our findings suggest that invasive car-
cinoma of the male breast displays a morphologic spectrum
and distribution of histologic subtypes that is comparable to
invasive carcinoma of the female breast and that no specific
histologic subtypes are notably over- or underrepresented
with the exception of papillary and lobular variants.
Papillary intraductal carcinomas basically assumed an
infiltrating duct carcinoma pattern once they invaded the
stroma (Fig. 1e,f). A papillary component was present in 34
(4.5%) of 759 cases, representing the second most common
histologic subtype. These papillary carcinomas appeared to
have invaded either through massive expansion and total
disruption of ductal confines with typical invasive patterns
at their periphery or only focally disrupted the duct wall
and invaded the surrounding stroma as an infiltrating duct
carcinoma. The latter represents approximately 2% [5]o f
female breast invasive carcinomas and appears overrepre-
sented in males. In a large population-based study,
Giordano et al. [7] reported that 2.6% of invasive malig-
nancies in males were papillary carcinomas, as compared
with 0.6% in females (p<0.0001). However,thedifferences
between males and females with respect to the frequencies of
the other histologic subtypes were also statistically sig-
nificant. The significance of the papillary histologic subtype
or papillary architecture in male ductal carcinoma requires
further investigation but is most probably related to the
architecture of the male mammary duct system with domi-
nance of largerducts.
The possibility of metastases to the breast should be
considered when evaluating breast masses particularly if
there is a history of cancer elsewhere. Nineteen cases of
carcinoma metastatic to the male breast were seen over this
study period, representing 2.4% (19/778) of all nonhema-
topoietic or lymphoreticular malignancies. This is again a
twofold increase comparable to the 1.2% reported in female
breast malignancies over a 10-year period [11]. Of the 19
metastatic tumors, 58% (11/19) were cutaneous melanomas,
and 21% (4/19), 10% (2/19), and 10% (2/19) represented
carcinomas from the prostate, lung, and larynx, respective-
ly. It is interesting to note that prostatic carcinoma, which
has been the subject of most reports of carcinomas
metastatic to the male breast [10], was not the most
common metastatic tumor in this series. The number of
metastatic tumors in this series is relatively small, which is
a limitation in interpreting the distribution of originating
sites. Nonetheless, in the investigation of metastatic tumors
to the male breast of an unknown primary site, our findings
provide additional data on some of the most likely sites.
This study also confirms the occurrence of lobular
carcinoma in the male breast. Three cases of invasive lobular
carcinoma, diagnosed purely on a morphologic basis, were
present among 759 cases (0.4%). Three additional cases of
mixed lobular and ductal carcinoma were also diagnosed
over this period (0.4%). Joshi et al. [16] found one (4%)
lobular carcinoma out of 27 cases, while Goss et al. [8]
found 4 (1.9%) cases out of a total of 229. In the series of
Giordano et al. [7], lobular carcinomas constituted 1.5% for
their male breast cancers. It is noteworthy that all of these
cases were interpreted as lobular based on morphology
without E-cadherin immunostain confirmation.
In summary, invasive carcinoma of the male breast
appears to display a morphologic spectrum and distribution
of histologic subtypes, which is comparable to invasive
carcinoma of the female breast with some variation. As
expected, lobular carcinoma is exceedingly rare but was
encountered in this series. There appears to be a twofold
increase in the frequency of invasive papillary carcinoma
and metastatic cancers to the male breast as compared to
published data in the female breast. Finally, the most
common tumor metastatic to the male breast in this series
was cutaneous melanoma.
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